https://www.selleckchem.com/pr....oducts/ly3522348.htm
In 2 out of 3eyes, further intravitreal treatment (9 and 13 respectively) was necessary due to the macular disease but no further increase in intraocular pressure occurred. The XEN® gel stent in combination with mitomycinC is atherapeutic option for difficult to adjust secondary glaucoma following intravitreal anti-VEGF therapy. A continuation of intravitreal anti-VEGF therapy did not lead to a recurrent increase of intraocular pressure. The XEN® gel stent in combination with mitomycin C is a therapeutic option for difficult to adjust